Andere talen Outlook Therapeutics, Inc.

Aandelen

OTLK

US69012T3059

Geschatte realtime Cboe BZX Andere beurzen 20:34:10 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,575 ^USD	+0,88%		+5,07%	+9,20%

27/03	Outlook Therapeutics-aandelen stijgen na BTIG-upgrade	MT
27/03	OUTLOOK THERAPEUTICS, INC. : BTIG verhoogt advies naar kopen	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Outlook Therapeutics® to Present at the Retina World Congress 2024	15:05
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	15/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Corporate Presentation: March 2024	28/03
North American Morning Briefing : Stocks Set for -2-	28/03
Outlook Therapeutics Shares Rise After BTIG Upgrade	27/03
Outlook Therapeutics Reports Secondary Share Offering	25/03
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	25/03
Sector Update: Health Care Stocks Ease Late Afternoon	22/03
Sector Update: Health Care Stocks Ease Friday Afternoon	22/03
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22/03
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	22/03
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	19/03
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab	19/03
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	18/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Outlook Therapeutics, Inc.

Aandelen

OTLK

US69012T3059

Andere talen

Filters